自1956年首次发现门冬酰胺酶以来,其临床应用越来越广泛。近20a中,左旋门冬酰胺酶(L-ASP)在急性淋巴细胞白血病(ALL)治疗中起到了举足轻重的作用,使ALL的缓解率及长期无病生存率都得到明显的提高。L-ASP可水解门冬酰胺使之变成门冬氨酸及氨,而门冬酰胺是机体合成蛋白质不可缺少 Since the first discovery of asparaginase in 1956, its clinical application has become more and more widespread. In the recent 20 years, L-ASP played a pivotal role in the treatment of acute lymphoblastic leukemia (ALL), and the remission rate and long-term disease-free survival of ALL were significantly improved. L-ASP can hydrolyze asparagine to make it aspartic acid and ammonia, while asparagine is an indispensable protein for synthesis of the body.